1
|
Araki T, Kanda S, Ide T, Sonehara K, Komatsu M, Tateishi K, Minagawa T, Kiniwa Y, Kawakami S, Nomura S, Okuyama R, Hanaoka M, Koizumi T. Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients. ESMO Open 2023; 8:102030. [PMID: 37852033 PMCID: PMC10774871 DOI: 10.1016/j.esmoop.2023.102030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 07/31/2023] [Accepted: 09/20/2023] [Indexed: 10/20/2023] Open
Abstract
BACKGROUND Immune checkpoint inhibitors (ICIs) are indicated for various cancers and are the mainstay of cancer immunotherapy. They are often associated with ICI-related pneumonitis (CIP), however, hindering a favorable clinical course. Recently, non-oncology concomitant drugs have been reported to affect the efficacy and toxicity of ICIs; however, the association between these drugs and the risk for CIP is uncertain. The aim of this study was to assess the impact of baseline concomitant drugs on CIP incidence in ICI-treated advanced cancer patients. PATIENTS AND METHODS This was a single-center retrospective study that included a cohort of 511 patients with advanced cancer (melanoma and non-small-cell lung, head and neck, genitourinary, and other types of cancer) treated with ICIs. Univariable analysis was conducted to identify baseline co-medications associated with CIP incidence. A propensity score matching analysis was used to adjust for potential CIP risk factors, and multivariable analysis was carried out to assess the impact of the identified co-medications on CIP risk. RESULTS Forty-seven (9.2%) patients developed CIP. In these patients, the organizing pneumonia pattern was the dominant radiological phenotype, and 42.6% had grade ≥3 CIP, including one patient with grade 5. Of the investigated baseline co-medications, the proportion of antiplatelet drugs (n = 50, 9.8%) was higher in patients with CIP (23.4% versus 8.4%). After propensity score matching, the CIP incidence was higher in patients with baseline antiplatelet drugs (22% versus 6%). Finally, baseline antiplatelet drug use was demonstrated to increase the risk for CIP incidence regardless of cancer type (hazard ratio, 3.46; 95% confidence interval 1.21-9.86). CONCLUSIONS An association between concomitant antiplatelet drug use at baseline and an increased risk for CIP was seen in our database. This implies the importance of assessing concomitant medications for CIP risk management.
Collapse
Affiliation(s)
- T Araki
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - S Kanda
- Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan.
| | - T Ide
- Department of Pharmacy, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Sonehara
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - M Komatsu
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Tateishi
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - T Minagawa
- Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan
| | - Y Kiniwa
- Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
| | - S Kawakami
- Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan
| | - S Nomura
- Department of Biostatistics and Bioinformatics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - R Okuyama
- Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
| | - M Hanaoka
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - T Koizumi
- Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan
| |
Collapse
|
2
|
Yokouchi H, Mizugaki H, Ikezawa Y, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Nakamura A, M. kobayashi, Aso M, Tsukita Y, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Kitamura Y. 335P Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
3
|
Ohki D, Tsuji Y, Yamazawa S, Ushiku T, Tateishi K. Gastrointestinal: Esophageal adenocarcinoma arising from circumferential ectopic gastric mucosa: A case report. J Gastroenterol Hepatol 2022; 37:47. [PMID: 34279045 DOI: 10.1111/jgh.15602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 06/23/2021] [Accepted: 06/26/2021] [Indexed: 12/09/2022]
Affiliation(s)
- D Ohki
- Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Y Tsuji
- Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - S Yamazawa
- Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - T Ushiku
- Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - K Tateishi
- Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
4
|
Kanda M, Tateishi K, Nakagomi A, Iwahana T, Okada S, Kuwabara H, Kobayashi Y, Inoue T. Relationship of early intensive- or coronary care unit admission and post-discharge performance of activities of daily living in patients with acute decompensated heart failure. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The management of acute decompensated heart failure (ADHF) often requires intensive care. However, the effects of early intensive care unit (ICU)/coronary care unit (CCU) admission on activities of daily living (ADL) in ADHF patients have not been precisely evaluated. Thus, we assessed whether early ICU entry can improve post-discharge ADL performance in these patients.
Methods and results
ADHF patients (New York Heart Association I–III) admitted on emergency between April 1, 2014, and December 31, 2018, were selected from the Diagnosis Procedure Combination database and divided into ICU/CCU (ICU) and general ward (GW) groups according to the hospitalization type on admission day 1. The propensity score was calculated to create matched cohorts where treatment assignment (ICU/CCU admission) is independent of measured baseline confounding factors including ADL at admission. The primary outcome was post-ADL defined according to the Barthel index (BI) at discharge. Secondary outcomes included length of stay (LOS) and total hospitalization cost (expense). Overall, 12,231 patients were eligible, and propensity score matching created 2,985 pairs. After matching, post-ADL was significantly higher in the ICU group (GW 71.5±35.3 vs. ICU 78.2±31.2, P<0.001, difference in mean 6.7 (95% CI 5.1–8.4) points). After matching, LOS was significantly shorter and expenses were significantly higher in the ICU group. Subanalyses showed that patients with low ADL at admission (BI<60) mainly benefited from early ICU/CCU entry.
Conclusions
Early ICU/CCU entry was beneficially associated with post-ADL in patients with emergency ADHF admission. ADL at admission might serve as a useful criterion for ICU admission.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Kanda
- Chiba University Graduate School of Medicine, Department of Cardiology, Chiba, Japan
| | - K Tateishi
- Chiba University Graduate School of Medicine, Department of Cardiology, Chiba, Japan
| | - A Nakagomi
- Harvard T. H. Chan School of Public Health, Takemi Program in International Health, Boston, United States of America
| | - T Iwahana
- Chiba University Graduate School of Medicine, Department of Cardiology, Chiba, Japan
| | - S Okada
- Chiba University Graduate School of Medicine, Department of Cardiology, Chiba, Japan
| | - H Kuwabara
- Chiba University Hospital, Department of Healthcare Management Research Center, Chiba, Japan
| | - Y Kobayashi
- Chiba University Graduate School of Medicine, Department of Cardiology, Chiba, Japan
| | - T Inoue
- Chiba University Hospital, Department of Healthcare Management Research Center, Chiba, Japan
| |
Collapse
|
5
|
Tateishi K, Kondo Y, Saito Y, Kitahara H, Kobayashi Y. Implantable cardioverter-defibrillator therapy after resuscitation from cardiac arrest in vasospastic angina. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Patients with vasospastic angina (VSA) who are resuscitated from sudden cardiac arrest (SCA) are at high risk of recurrent cardiovascular events. However, there are no recommendations for implantable cardioverter-defibrillator (ICD) therapy in the VSA and SCA patient guidelines.
Purpose
This study investigated the prognostic impact of ICD therapy on patients with VSA and SCA.
Methods
The present multi-center registry included 280 patients who were resuscitated from SCA and received ICD implantation as secondary prophylaxis. The patients were divided into two groups according to the presence of VSA. The primary endpoint was a composite of all-cause death and appropriate ICD therapy, including appropriate anti-tachycardia pacing and shock for recurrent ventricular arrhythmias.
Results
Of 280 patients, 51 (18%) had VSA. Among those without VSA, ischemic cardiomyopathy was the leading cause of SCA (38%), followed by non-ischemic cardiomyopathies and Brugada syndrome (Table 1). During the median follow-up period of 3.8 years, 23 (8%) patients died, and 72 (26%) underwent appropriate ICD therapy. The incidence of the primary endpoint was not significantly different between patients with and without VSA (24% vs 33%, p=0.19). Further, the incidence of the primary endpoint was not significantly different among the etiologies (Figure 1)
Conclusions
In a cohort of patients who underwent ICD implantation as secondary prophylaxis, long-term clinical outcomes were comparable between those with VSA and those with other cardiac diseases after SCA. The results suggest that ICD therapy may be considered in patients with VSA and those with other etiologies after resuscitation from SCA.
Funding Acknowledgement
Type of funding sources: None. Table 1. Patient characteristics and outcomesFigure 1. Incidence of the primary endpoint
Collapse
Affiliation(s)
- K Tateishi
- Chiba University Hospital, Cardiology, Chiba, Japan
| | - Y Kondo
- Chiba University Hospital, Cardiology, Chiba, Japan
| | - Y Saito
- Chiba University Hospital, Cardiology, Chiba, Japan
| | - H Kitahara
- Chiba University Hospital, Cardiology, Chiba, Japan
| | - Y Kobayashi
- Chiba University Hospital, Cardiology, Chiba, Japan
| |
Collapse
|
6
|
Kobayashi M, Mizugaki H, Ikezawa Y, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Nagano Y, Nakamura A, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Fujita Y, Oizumi S. P16.05 Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Nakamura A, Mizugaki H, Ikezawa Y, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Morita M, Aso M, Tsukita Y, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Yokouchi H. 1306P Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
8
|
Toyokawa G, Kanavati F, Momosaki S, Tateishi K, Takeoka H, Okamoto M, Yamazaki K, Takeo S, Iizuka O, Tsuneki M. Deep learning to predict subtypes of poorly differentiated lung cancer from biopsy whole slide images. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.8536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8536 Background: Lung cancer is the leading cause of cancer-related death in many countries, and its prognosis remains unsatisfactory. Since treatment approaches differ substantially based on the subtype, such as adenocarcinoma (ADC), squamous cell carcinoma (SCC) and small cell lung cancer (SCLC), an accurate histopathological diagnosis is of great importance. However, if the specimen is solely composed of poorly differentiated cancer cells, distinguishing between histological subtypes can be difficult. The present study developed a deep learning model to classify lung cancer subtypes from whole slide images (WSIs) of transbronchial lung biopsy (TBLB) specimens, in particular with the aim of using this model to evaluate a challenging test set of indeterminate cases. Methods: Our deep learning model consisted of two separately trained components: a convolutional neural network tile classifier and a recurrent neural network tile aggregator for the WSI diagnosis. We used a training set consisting of 638 WSIs of TBLB specimens to train a deep learning model to classify lung cancer subtypes (ADC, SCC and SCLC) and non-neoplastic lesions. The training set consisted of 593 WSIs for which the diagnosis had been determined by pathologists based on the visual inspection of Hematoxylin-Eosin (HE) slides and of 45 WSIs of indeterminate cases (64 ADCs and 19 SCCs). We then evaluated the models using five independent test sets. For each test set, we computed the receiver operator curve (ROC) area under the curve (AUC). Results: We applied the model to an indeterminate test set of WSIs obtained from TBLB specimens that pathologists had not been able to conclusively diagnose by examining the HE-stained specimens alone. Overall, the model achieved ROC AUCs of 0.993 (confidence interval [CI] 0.971-1.0) and 0.996 (0.981-1.0) for ADC and SCC, respectively. We further evaluated the model using five independent test sets consisting of both TBLB and surgically resected lung specimens (combined total of 2490 WSIs) and obtained highly promising results with ROC AUCs ranging from 0.94 to 0.99. Conclusions: In this study, we demonstrated that a deep learning model could be trained to predict lung cancer subtypes in indeterminate TBLB specimens. The extremely promising results obtained show that if deployed in clinical practice, a deep learning model that is capable of aiding pathologists in diagnosing indeterminate cases would be extremely beneficial as it would allow a diagnosis to be obtained sooner and reduce costs that would result from further investigations.
Collapse
Affiliation(s)
- Gouji Toyokawa
- Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan
| | | | - Seiya Momosaki
- Department of Pathology, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan
| | | | - Hiroaki Takeoka
- Department of Pathology, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan
| | - Masaki Okamoto
- Department of Respiratory Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan
| | - Koji Yamazaki
- Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan
| | - Sadanori Takeo
- Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan
| | | | | |
Collapse
|
9
|
Saito Y, Mori N, Saito K, Matsuoka T, Tateishi K, Kitahara H, Fujimoto Y, Kobayashi Y. Greater coronary lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound in patients with elevated xanthine oxidoreductase: a mechanistic insight. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Elevated serum uric acid level was reportedly associated with greater coronary lipid plaque. Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine metabolism and believed to play important roles in coronary atherosclerosis. However, the relation of XOR to coronary lipid plaque and its mechanism are unclear.
Purpose
The aim of this study was to assess the impact of XOR on coronary lipid plaque and the associated factors with XOR in coronary artery disease (CAD).
Methods
Patients with stable CAD undergoing elective percutaneous coronary intervention under near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) guidance were prospectively enrolled. They were divided into three groups according to serum XOR activities; low, normal, and high. Coronary lipid core plaques in non-target vessels were evaluated by NIRS-IVUS with lipid core burden index (LCBI) and a maximum LCBI in 4 mm (maxLCBI4mm). Systemic endothelial function and inflammation were assessed with reactive hyperemia index (RHI) and high-sensitivity C-reactive protein, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio.
Results
Of 68 patients, 26, 31, and 11 were classified as low, normal, and high XOR activity groups. LCBI (474.4±171.6 vs. 347.4±181.6 vs. 294.0±155.9, p=0.04) and maxLCBI4mm (102.1±56.5 vs. 65.6±48.5 vs. 55.6±37.8, p=0.04) were significantly higher in high XOR group than in normal and low XOR groups. Although RHI was significantly correlated with body mass index, diabetes, current smoking, and high-density lipoprotein cholesterol, no relation was found between XOR activity and RHI (Figure). There were also no relations between XOR activity and high-sensitivity C-reactive protein, neutrophil-to-lymphocyte ratio, or platelet-to-lymphocyte ratio (Figure).
Conclusion
Elevated XOR activity was associated with greater coronary lipid plaque in patients with stable CAD, without significant relations to systemic endothelial function and inflammation.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- Y Saito
- Chiba University Graduate School of Medicine, Department of Cardiovascular Medicine, Chiba, Japan
| | - N Mori
- Chiba University Graduate School of Medicine, Department of Cardiovascular Medicine, Chiba, Japan
| | - K Saito
- Chiba University Graduate School of Medicine, Department of Cardiovascular Medicine, Chiba, Japan
| | - T Matsuoka
- Chiba University Graduate School of Medicine, Department of Cardiovascular Medicine, Chiba, Japan
| | - K Tateishi
- Chiba University Graduate School of Medicine, Department of Cardiovascular Medicine, Chiba, Japan
| | - H Kitahara
- Chiba University Graduate School of Medicine, Department of Cardiovascular Medicine, Chiba, Japan
| | - Y Fujimoto
- Chiba University Graduate School of Medicine, Department of Cardiovascular Medicine, Chiba, Japan
| | - Y Kobayashi
- Chiba University Graduate School of Medicine, Department of Cardiovascular Medicine, Chiba, Japan
| |
Collapse
|
10
|
Kato K, Tateishi K, Saito Y, Kitahara H, Fujimoto Y, Kobayashi Y. Comparison of clinical characteristics between patients with microvascular and epicardial coronary artery spasm. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Coronary functional abnormalities including both epicardial and microvascular coronary artery spasm represent an important role responsible for myocardial ischemia in patients with angina and nonobstructive coronary artery disease. However, clinical characteristics associated with microvascular spasm (MVS) have not been fully evaluated.
Purpose
The aim of this study was to assess differences in clinical features between patients with MVS and epicardial coronary spasm.
Methods
A total of 732 consecutive patients with suspected angina who presented nonobstructive coronary arteries and underwent intracoronary acetylcholine provocation test were retrospectively enrolled in this study. Epicardial coronary spasm was defined as total or subtotal occlusion of epicardial coronary arteries accompanied by chest pain and/or ischemic electrocardiographic changes in response to acetylcholine provocation test. MVS was diagnosed when chest pain and/or ischemic electrocardiographic changes developed after administration of acetylcholine in the absence of epicardial coronary spasm. Clinical characteristics were compared between patients with MVS and epicardial coronary spasm.
Results
Of all patients, 83 patients (11%) had MVS, 367 (50%) had epicardial coronary spasm, and the other patients (39%) showed neither MVS nor epicardial coronary spasm. Patients with MVS tended to be older (65.6±12.7 vs. 63.0±12.3 years, P=0.088) and were more frequently female (60.2% vs. 41.1%, P=0.0016) in comparison with patients with epicardial coronary spasm. Patients with MVS were less likely to be smokers (8.6% vs. 22.9%, P=0.0018), while there were no significant differences in the other coronary risk factors such as hypertension, dyslipidemia, and diabetes mellitus. Serum uric acid were significantly lower in patients with MVS (4.9±1.1 vs. 5.4±1.3 mg/dl, P=0.0018).
Conclusion
Our study demonstrated that patients with MVS had distinctive clinical background from those with epicardial coronary spasm, suggesting different mechanisms may involve the development of MVS.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Kato
- Chiba University Graduate School of Medicine, Chiba, Japan
| | - K Tateishi
- Chiba University Graduate School of Medicine, Chiba, Japan
| | - Y Saito
- Chiba University Graduate School of Medicine, Chiba, Japan
| | - H Kitahara
- Chiba University Graduate School of Medicine, Chiba, Japan
| | - Y Fujimoto
- Chiba University Graduate School of Medicine, Chiba, Japan
| | - Y Kobayashi
- Chiba University Graduate School of Medicine, Chiba, Japan
| |
Collapse
|
11
|
Kato K, Tateishi K, Saito Y, Kitahara H, Fujimoto Y, Kobayashi Y. Age-related differences and vascular function test findings in patients with vasospastic angina. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Vasospastic angina (VSA) accounts for the majority of angina cases with no epicardial stenosis and develops amongawide range of age, which is reportedly induced by coronary functional abnormalities including endothelial dysfunction and smooth muscle hypercontraction. However, the relation of noninvasive vascular function tests to VSA remains to be fully elucidated.
Purpose
The aim of this study was to assess differences in clinical characteristics and findings from noninvasive vascular function tests among groups by age in patients with VSA.
Methods
We enrolled a total of 732 patients with angina who underwent intracoronary acetylcholine provocation test. VSA was defined as total or subtotal occlusion of epicardial coronary arteries accompanied by chest pain and/or ischemic electrocardiographic changes in response to acetylcholine administration. Patients with VSA were divided into 3 groups by age (young [<50 years], intermediate [50–64 years], and elderly group [≥65 years]). Noninvasive vascular function test findings such as ankle-brachial index (ABI), brachial-ankle pulse wave velocity (baPWV), andpercentage of mean arterial pressure (%MAP) were compared among groups by age in patients with VSA.
Results
Of all patients, 367 (50.1%) were diagnosed as VSA with intracoronary acetylcholine test, including 66 (18.0%), 113 (30.8%), and 188 (51.2%) patients in the young, intermediate, and elderly groups. Among groups by age, there was no significant difference in gender (female, 31.8% vs. 40.7% vs. 44.7%, P=0.19). Patients in the young group were more often smokers and alcohol drinkers than those in the intermediate and elderly groups, while the prevalence of hypertension, dyslipidemia, and diabetes were lower in younger patients. A history of percutaneous coronary intervention was less frequently found in the young group compared tothe intermediate and elderly groups (7.6% vs. 16.8% vs. 20.7%, P=0.033). The baPWV was higher in the elderly group (1424±232 vs. 1537±247 vs. 1774±358 cm/s, P<0.0001), while there was no difference in ABI between the 3 groups. %MAP at arms was significantly and progressively decreased with an increase in age (54.0±4.5% vs. 53.0±2.6% vs. 51.2±2.8%, P<0.0001).
Conclusion
Our study demonstrated that there were distinct age-related differences in clinical characteristics of patients with VSA. The higher %MAP in younger patients suggests that more impaired endothelial dysfunction may play a role in the development of VSA in this age group.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Kato
- Chiba University Graduate School of Medicine, Chiba, Japan
| | - K Tateishi
- Chiba University Graduate School of Medicine, Chiba, Japan
| | - Y Saito
- Chiba University Graduate School of Medicine, Chiba, Japan
| | - H Kitahara
- Chiba University Graduate School of Medicine, Chiba, Japan
| | - Y Fujimoto
- Chiba University Graduate School of Medicine, Chiba, Japan
| | - Y Kobayashi
- Chiba University Graduate School of Medicine, Chiba, Japan
| |
Collapse
|
12
|
Nagashima H, Lee C, Tateishi K, Higuchi F, Subramanian M, Rafferty S, Melamed L, Miller J, Wakimoto H, Cahill D. Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)31100-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Tateishi K, Kitahara H, Nakayama T, Fujimoto Y, Kobayashi Y. P5538Safety and efficacy of acetylcholine provocation test for diagnosis of vasospastic angina in young patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Vasospastic angina (VSA) is considered as a cause of myocardial infarction with nonobstructive coronary arteries. Given the previous reports of higher incidence of cardiovascular events in young VSA patients, early diagnosis and optimal treatment are important for these patients. While acetylcholine provocation test (ACh test) for VSA diagnosis is well reported, ACh test among young patients is not as commonly performed, therefore its safety and usefulness for this patient subset have not been fully evaluated.
Purpose
The purpose of this study was to evaluate the safety and the proportion of positive results of ACh test for young patients.
Methods
Data from patients who underwent ACh test in our institution from May 2012 to September 2018 were retrospectively analyzed. A total of 669 patients were enrolled and divided into 2 groups according to age: Young group (Age≤50, n=106); and Senior group (Age>50, n=563).
Results
The senior group had a higher incidence of hypertension, dyslipidemia, diabetes mellitus, and coronary artery disease. On the other hand, the young group had a significantly higher incidence of current smoker and tendency of daily alcohol. The rate of positive ACh test was similar, and there were no significant differences in major or minor complications between the 2 groups.
Patient characteristics and outcome Young group Senior group p (n=106) (n=563) Age (years) 42.8±7.3 68.0±9.0 <0.001 Male (%) 56.6 52.2 0.407 Current smoker (%) 34.9 15.4 <0.001 Daily alcohol (%) 31.1 22.9 0.070 Hypertension (%) 33.0 66.6 <0.001 Dyslipidemia (%) 50.0 68.4 <0.001 Diabetes (%) 12.3 20.8 0.047 ACh positive (%) 52.8 49.9 0.581 Minor adverse event (%) 4.7 5.9 0.820 Major adverse event (%) 0.9 1.4 1.000 Major adverse event: composite of death, ventricular fibrillation, sustained ventricular tachycardia (VT), myocardial infarction and stroke. Minor adverse event: non-sustained VT and paroxysmal atrial fibrillation.
Conclusion
ACh provocation test for young patients can be safely performed, and the rate of positive results was similar to that of senior patients. In young patients suspected of having VSA, ACh test should be actively performed to identify optimal medical therapy for prevention of cardiovascular events.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- K Tateishi
- Chiba University Hospital, Cardiology, Chiba, Japan
| | - H Kitahara
- Chiba University Hospital, Cardiology, Chiba, Japan
| | - T Nakayama
- Chiba University Hospital, Cardiology, Chiba, Japan
| | - Y Fujimoto
- Chiba University Hospital, Cardiology, Chiba, Japan
| | - Y Kobayashi
- Chiba University Hospital, Cardiology, Chiba, Japan
| |
Collapse
|
14
|
Kaneshiro K, Sakai Y, Suzuki K, Uchida K, Tateishi K, Terashima Y, Kawasaki Y, Shibanuma N, Yoshida K, Hashiramoto A. Interleukin-6 and tumour necrosis factor-α cooperatively promote cell cycle regulators and proliferate rheumatoid arthritis fibroblast-like synovial cells. Scand J Rheumatol 2019; 48:353-361. [DOI: 10.1080/03009742.2019.1602164] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- K Kaneshiro
- Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
| | - Y Sakai
- Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - K Suzuki
- Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
| | - K Uchida
- Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
| | - K Tateishi
- Department of Orthopedics, Kohnan Kakogawa Hospital, Kakogawa, Japan
| | - Y Terashima
- Department of Orthopedics, Kohnan Kakogawa Hospital, Kakogawa, Japan
| | - Y Kawasaki
- Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan
| | - N Shibanuma
- Department of Orthopedic Surgery, Kobe Kaisei Hospital, Kobe, Japan
| | - K Yoshida
- Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
| | - A Hashiramoto
- Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
| |
Collapse
|
15
|
|
16
|
Takenaka S, Hosono N, Mukai Y, Tateishi K, Fuji T. Significant reduction in the incidence of C5 palsy after cervical laminoplasty using chilled irrigation water. Bone Joint J 2016; 98-B:117-24. [DOI: 10.1302/0301-620x.98b1.36042] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Aims The aim of this study was to determine whether chilled irrigation saline decreases the incidence of clinical upper limb palsy (ULP; a reduction of one grade or more on manual muscle testing; MMT), based on the idea that ULP results from thermal damage to the nerve roots by heat generated by friction during bone drilling. Methods Irrigation saline for drilling was used at room temperature (RT, 25.6°C) in open-door laminoplasty in 400 patients (RT group) and chilled to a mean temperature of 12.1°C during operations for 400 patients (low-temperature (LT) group). We assessed deltoid, biceps, and triceps brachii muscle strength by MMT. ULP occurring within two days post-operatively was categorised as early-onset palsy. Results The incidence of ULP (4.0% vs 9.5%, p = 0.003), especially early-onset palsy (1.0% vs 5.5%, p < 0.001), was significantly lower for the LT group than for the RT group. Multivariate analysis indicated that RT irrigation saline use, concomitant foraminotomy, and opened side were significant predictors for ULP. Discussion Using chilled irrigation saline during bone drilling significantly decreased the ULP incidence, particularly the early-onset type, and shortened the recovery period for ULP. Chilled irrigation saline can thus be recommended as a simple method for preventing ULP. Take home message: Chilled irrigation during laminoplasty reduces C5 palsy. Cite this article: Bone Joint J 2016;98-B:117–24.
Collapse
Affiliation(s)
- S. Takenaka
- Japan Community Healthcare Organization
Osaka Hospital, Fukushima 4-2-78, Osaka 553-0003, Japan
| | - N. Hosono
- Japan Community Healthcare Organization
Osaka Hospital, Fukushima 4-2-78, Osaka 553-0003, Japan
| | - Y. Mukai
- Japan Community Healthcare Organization
Osaka Hospital, Fukushima 4-2-78, Osaka 553-0003, Japan
| | - K. Tateishi
- Japan Community Healthcare Organization
Osaka Hospital, Fukushima 4-2-78, Osaka 553-0003, Japan
| | - T. Fuji
- Japan Community Healthcare Organization
Osaka Hospital, Fukushima 4-2-78, Osaka 553-0003, Japan
| |
Collapse
|
17
|
Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 2015; 42:279-90. [PMID: 26111727 DOI: 10.1111/nan.12259] [Citation(s) in RCA: 145] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Accepted: 06/21/2015] [Indexed: 12/12/2022]
Abstract
AIMS Primary central nervous system lymphoma (PCNSL) manifest aggressive clinical behaviour and have poor prognosis. Although constitutive activation of the nuclear factor-κB (NF-κB) pathway has been documented, knowledge about the genetic alterations leading to the impairment of the NF-κB pathway in PCNSLs is still limited. This study was aimed to unravel the underlying genetic profiles of PCNSL. METHODS We conducted the systematic sequencing of 21 genes relevant to the NF-κB signalling network for 71 PCNSLs as well as the pyrosequencing of CD79B and MYD88 mutation hotspots in a further 35 PCNSLs and 46 glioblastomas (GBMs) for validation. RESULTS The results showed that 68 out of 71 PCNSLs had mutations in the NF-κB gene network, most commonly affecting CD79B (83%), MYD88 (76%), TBL1XR1 (23%), PRDM1 (20%) and CREBBP1 (20%). These mutations, particularly CD79B and MYD88, frequently coincided within each tumour in various combinations, simultaneously affecting diverse pathways within the network. No GBMs had hotspot mutation of CD79B Y196 and MYD88 L265. CONCLUSIONS The prevalence of CD79B and MYD88 mutations in PCNSLs was considerably higher than reported in systemic diffuse large B-cell lymphomas. This observation could reflect the paucity of antigen stimuli from the immune system in the central nervous system (CNS) and the necessity to substitute them by the constitutive activation of CD79B and MYD88 that would initiate the signalling cascades. These hotspot mutations may serve as a genetic hallmark for PCNSL serving as a genetic marker for diagnose and potential targets for molecular therapy.
Collapse
Affiliation(s)
- T Nakamura
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
| | - K Tateishi
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
| | - T Niwa
- Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan
| | - Y Matsushita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - K Tamura
- Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan
| | - M Kinoshita
- Department of Neurosurgery, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - K Tanaka
- Department of Neurosurgery, Graduate School of Medicine, Kobe University, Kobe, Japan
| | - S Fukushima
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - H Takami
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - H Arita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - A Kubo
- Department of Neurosurgery, Yokosuka Kyosai Hospital, Yokosuka, Japan
| | - T Shuto
- Department of Neurosurgery, Yokohama Rosai Hospital, Yokohama, Japan
| | - M Ohno
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - Y Miyakita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - S Kocialkowski
- Department of Pathology, University of Cambridge, Cambridge, UK
| | - T Sasayama
- Department of Neurosurgery, Graduate School of Medicine, Kobe University, Kobe, Japan
| | - N Hashimoto
- Department of Neurosurgery, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - T Maehara
- Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan
| | - S Shibui
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - T Ushijima
- Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan
| | - N Kawahara
- Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
| | - Y Narita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - K Ichimura
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| |
Collapse
|
18
|
Tateishi K, Kishimoto A, Higa M, Yasuda N. Salivary α-amylase and IgA responses to repeated bouts of short high-intensity exercise tests in recreationally active men. J Sci Med Sport 2014. [DOI: 10.1016/j.jsams.2014.11.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
19
|
Tateishi K, Lelic N, Ho QH, Esakl S, Iafrate JA, Cahill DP, Chi AS, Wakimoto H. NT-33 * NAD+ SYNTHESIS INHIBITION AS A THERAPEUTIC STRATEGY FOR GLIOBLASTOMA WITH MYC AMPLIFICATION. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou265.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Takhistov V, Abe K, Haga Y, Hayato Y, Ikeda M, Iyogi K, Kameda J, Kishimoto Y, Miura M, Moriyama S, Nakahata M, Nakano Y, Nakayama S, Sekiya H, Shiozawa M, Suzuki Y, Takeda A, Tanaka H, Tomura T, Ueno K, Wendell RA, Yokozawa T, Irvine T, Kajita T, Kametani I, Kaneyuki K, Lee KP, McLachlan T, Nishimura Y, Richard E, Okumura K, Labarga L, Fernandez P, Berkman S, Tanaka HA, Tobayama S, Gustafson J, Kearns E, Raaf JL, Stone JL, Sulak LR, Goldhaber M, Carminati G, Kropp WR, Mine S, Weatherly P, Renshaw A, Smy MB, Sobel HW, Ganezer KS, Hartfiel BL, Hill J, Keig WE, Hong N, Kim JY, Lim IT, Akiri T, Himmel A, Scholberg K, Walter CW, Wongjirad T, Ishizuka T, Tasaka S, Jang JS, Learned JG, Matsuno S, Smith SN, Hasegawa T, Ishida T, Ishii T, Kobayashi T, Nakadaira T, Nakamura K, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Suzuki AT, Takeuchi Y, Bronner C, Hirota S, Huang K, Ieki K, Kikawa T, Minamino A, Murakami A, Nakaya T, Suzuki K, Takahashi S, Tateishi K, Fukuda Y, Choi K, Itow Y, Mitsuka G, Mijakowski P, Hignight J, Imber J, Jung CK, Yanagisawa C, Ishino H, Kibayashi A, Koshio Y, Mori T, Sakuda M, Yamaguchi R, Yano T, Kuno Y, Tacik R, Kim SB, Okazawa H, Choi Y, Nishijima K, Koshiba M, Suda Y, Totsuka Y, Yokoyama M, Martens K, Marti L, Vagins MR, Martin JF, de Perio P, Konaka A, Wilking MJ, Chen S, Zhang Y, Connolly K, Wilkes RJ. Search for trilepton nucleon decay via p→e+νν and p→μ+νν in the Super-Kamiokande experiment. Phys Rev Lett 2014; 113:101801. [PMID: 25238348 DOI: 10.1103/physrevlett.113.101801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/06/2014] [Indexed: 06/03/2023]
Abstract
The trilepton nucleon decay modes p→e+νν and p→μ+νν violate |Δ(B-L)| by two units. Using data from a 273.4 kt yr exposure of Super-Kamiokande a search for these decays yields a fit consistent with no signal. Accordingly, lower limits on the partial lifetimes of τp→e+νν>1.7×10(32) years and τp→μ+νν>2.2×10(32) years at a 90% confidence level are obtained. These limits can constrain Grand Unified Theories which allow for such processes.
Collapse
Affiliation(s)
- V Takhistov
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - Y Haga
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - Y Hayato
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - M Ikeda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - K Iyogi
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - J Kameda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - Y Kishimoto
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - M Miura
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - M Nakahata
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - Y Nakano
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - S Nakayama
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - H Sekiya
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - M Shiozawa
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - Y Suzuki
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - H Tanaka
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - T Tomura
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - K Ueno
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - R A Wendell
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - T Yokozawa
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - T Irvine
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - T Kajita
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - I Kametani
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - K Kaneyuki
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - K P Lee
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - T McLachlan
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - Y Nishimura
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - E Richard
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - K Okumura
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - L Labarga
- Department of Theoretical Physics, University Autonoma Madrid, 28049 Madrid, Spain
| | - P Fernandez
- Department of Theoretical Physics, University Autonoma Madrid, 28049 Madrid, Spain
| | - S Berkman
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, V6T1Z4, Canada
| | - H A Tanaka
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, V6T1Z4, Canada
| | - S Tobayama
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, V6T1Z4, Canada
| | - J Gustafson
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - E Kearns
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - J L Raaf
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - J L Stone
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - L R Sulak
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - M Goldhaber
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Carminati
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - W R Kropp
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - S Mine
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - P Weatherly
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - A Renshaw
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - M B Smy
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - H W Sobel
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - K S Ganezer
- Department of Physics, California State University, Dominguez Hills, Carson, California 90747, USA
| | - B L Hartfiel
- Department of Physics, California State University, Dominguez Hills, Carson, California 90747, USA
| | - J Hill
- Department of Physics, California State University, Dominguez Hills, Carson, California 90747, USA
| | - W E Keig
- Department of Physics, California State University, Dominguez Hills, Carson, California 90747, USA
| | - N Hong
- Department of Physics, Chonnam National University, Kwangju 500-757, Korea
| | - J Y Kim
- Department of Physics, Chonnam National University, Kwangju 500-757, Korea
| | - I T Lim
- Department of Physics, Chonnam National University, Kwangju 500-757, Korea
| | - T Akiri
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - A Himmel
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - K Scholberg
- Department of Physics, Duke University, Durham, North Carolina 27708, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - C W Walter
- Department of Physics, Duke University, Durham, North Carolina 27708, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - T Wongjirad
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - T Ishizuka
- Junior College, Fukuoka Institute of Technology, Fukuoka, Fukuoka 811-0295, Japan
| | - S Tasaka
- Department of Physics, Gifu University, Gifu, Gifu 501-1193, Japan
| | - J S Jang
- GIST College, Gwangju Institute of Science and Technology, Gwangju 500-712, Korea
| | - J G Learned
- Department of Physics and Astronomy, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - S Matsuno
- Department of Physics and Astronomy, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - S N Smith
- Department of Physics and Astronomy, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - T Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Ishii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K Nakamura
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - Y Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - A T Suzuki
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - Y Takeuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - C Bronner
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - S Hirota
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - K Huang
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - K Ieki
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - T Kikawa
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - A Minamino
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - A Murakami
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - T Nakaya
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - K Suzuki
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - S Takahashi
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - K Tateishi
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - Y Fukuda
- Department of Physics, Miyagi University of Education, Sendai, Miyagi 980-0845, Japan
| | - K Choi
- Solar Terrestrial Environment Laboratory, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - Y Itow
- Solar Terrestrial Environment Laboratory, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - G Mitsuka
- Solar Terrestrial Environment Laboratory, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - P Mijakowski
- National Centre For Nuclear Research, 00-681 Warsaw, Poland
| | - J Hignight
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York 11794-3800, USA
| | - J Imber
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York 11794-3800, USA
| | - C K Jung
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York 11794-3800, USA
| | - C Yanagisawa
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York 11794-3800, USA
| | - H Ishino
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - A Kibayashi
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - Y Koshio
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - T Mori
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - M Sakuda
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - R Yamaguchi
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - T Yano
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - Y Kuno
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - R Tacik
- Department of Physics, University of Regina, 3737 Wascana Parkway, Regina, Saskatchewan, S4SOA2, Canada and TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia, V6T2A3, Canada
| | - S B Kim
- Department of Physics, Seoul National University, Seoul 151-742, Korea
| | - H Okazawa
- Department of Informatics in Social Welfare, Shizuoka University of Welfare, Yaizu, Shizuoka, 425-8611, Japan
| | - Y Choi
- Department of Physics, Sungkyunkwan University, Suwon 440-746, Korea
| | - K Nishijima
- Department of Physics, Tokai University, Hiratsuka, Kanagawa 259-1292, Japan
| | - M Koshiba
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Suda
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Totsuka
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - M Yokoyama
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - K Martens
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - Ll Marti
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - M R Vagins
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - J F Martin
- Department of Physics, University of Toronto, 60 Saint George Street, Toronto, Ontario, M5S1A7, Canada
| | - P de Perio
- Department of Physics, University of Toronto, 60 Saint George Street, Toronto, Ontario, M5S1A7, Canada
| | - A Konaka
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia, V6T2A3, Canada
| | - M J Wilking
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia, V6T2A3, Canada
| | - S Chen
- Department of Engineering Physics, Tsinghua University, Beijing, 100084, China
| | - Y Zhang
- Department of Engineering Physics, Tsinghua University, Beijing, 100084, China
| | - K Connolly
- Department of Physics, University of Washington, Seattle, Washington 98195-1560, USA
| | - R J Wilkes
- Department of Physics, University of Washington, Seattle, Washington 98195-1560, USA
| |
Collapse
|
21
|
Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K, Kahn SA, Gholamin S, Junier MP, Chneiweiss H, Weissman I, Mitra S, Cheshier S, Avril T, Hamlat A, Le Reste PJ, Mosser J, Quillien V, Carrato C, Munoz-Marmol A, Serrano L, Pijuan L, Hostalot C, Villa SL, Ariza A, Etxaniz O, Balana C, Benveniste ET, Zheng Y, McFarland B, Drygin D, Bellis S, Bredel M, Lotsch D, Engelmaier C, Allerstorfer S, Grusch M, Pichler J, Weis S, Hainfellner J, Marosi C, Spiegl-Kreinecker S, Berger W, Bronisz A, Nowicki MO, Wang Y, Ansari K, Chiocca EA, Godlewski J, Brown K, Kwatra M, Brown K, Kwatra M, Bui T, Nitta R, Li G, Zhu S, Kozono D, Li J, Kushwaha D, Carter B, Chen C, Schulte J, Srikanth M, Das S, Zhang J, Lathia J, Yin L, Rich J, Olson E, Kessler J, Chenn A, Cherry A, Haas B, Lin YH, Ong SE, Stella N, Cifarelli CP, Griffin RJ, Cong D, Zhu W, Shi Y, Clark P, Kuo J, Hu S, Sun D, Bookland M, Darbinian N, Dey A, Robitaille M, Remke M, Faury D, Maier C, Malhotra A, Jabado N, Taylor M, Angers S, Kenney A, Ren X, Zhou H, Schur M, Baweja A, Singh M, Erdreich-Epstein A, Fu J, Koul D, Yao J, Saito N, Zheng S, Verhaak R, Lu Z, Yung WKA, Gomez G, Volinia S, Croce C, Brennan C, Cavenee W, Furnari F, Lopez SG, Qu D, Petritsch C, Gonzalez-Huarriz M, Aldave G, Ravi D, Rubio A, Diez-Valle R, Marigil M, Jauregi P, Vera B, Rocha AADL, Tejada-Solis S, Alonso MM, Gopal U, Isaacs J, Gruber-Olipitz M, Dabral S, Ramkissoon S, Kung A, Pak E, Chung J, Theisen M, Sun Y, Monrose V, Franchetti Y, Sun Y, Shulman D, Redjal N, Tabak B, Beroukhim R, Zhao J, Buonamici S, Ligon K, Kelleher J, Segal R, Haas B, Canton D, Diaz P, Scott J, Stella N, Hara K, Kageji T, Mizobuchi Y, Kitazato K, Okazaki T, Fujihara T, Nakajima K, Mure H, Kuwayama K, Hara T, Nagahiro S, Hill L, Botfield H, Hossain-Ibrahim K, Logan A, Cruickshank G, Liu Y, Gilbert M, Kyprianou N, Rangnekar V, Horbinski C, Hu Y, Vo C, Li Z, Ke C, Ru N, Hess KR, Linskey ME, Zhou YAH, Hu F, Vinnakota K, Wolf S, Kettenmann H, Jackson PJ, Larson JD, Beckmann DA, Moriarity BS, Largaespada DA, Jalali S, Agnihotri S, Singh S, Burrell K, Croul S, Zadeh G, Kang SH, Yu MO, Song NH, Park KJ, Chi SG, Chung YG, Kim SK, Kim JW, Kim JY, Kim JE, Choi SH, Kim TM, Lee SH, Kim SK, Park SH, Kim IH, Park CK, Jung HW, Koldobskiy M, Ahmed I, Ho G, Snowman A, Raabe E, Eberhart C, Snyder S, Agnihotri S, Gugel I, Remke M, Bornemann A, Pantazis G, Mack S, Shih D, Sabha N, Taylor M, Tatagiba M, Zadeh G, Krischek B, Schulte A, Liffers K, Kathagen A, Riethdorf S, Westphal M, Lamszus K, Lee JS, Xiao J, Patel P, Schade J, Wang J, Deneen B, Erdreich-Epstein A, Song HR, Leiss L, Gjerde C, Saed H, Rahman A, Lellahi M, Enger PO, Leung R, Gil O, Lei L, Canoll P, Sun S, Lee D, Ho ASW, Pu JKS, Zhang XQ, Lee NP, Dat PJR, Leung GKK, Loetsch D, Steiner E, Holzmann K, Spiegl-Kreinecker S, Pirker C, Hlavaty J, Petznek H, Hegedus B, Garay T, Mohr T, Sommergruber W, Grusch M, Berger W, Lukiw WJ, Jones BM, Zhao Y, Bhattacharjee S, Culicchia F, Magnus N, Garnier D, Meehan B, McGraw S, Hashemi M, Lee TH, Milsom C, Gerges N, Jabado N, Trasler J, Pawlinski R, Mackman N, Rak J, Maherally Z, Thorne A, An Q, Barbu E, Fillmore H, Pilkington G, Maherally Z, Tan SL, Tan S, An Q, Fillmore H, Pilkington G, Malhotra A, Choi S, Potts C, Ford DA, Nahle Z, Kenney AM, Matlaf L, Khan S, Zider A, Singer E, Cobbs C, Soroceanu L, McFarland BC, Hong SW, Rajbhandari R, Twitty GB, Gray GK, Yu H, Benveniste EN, Nozell SE, Minata M, Kim S, Mao P, Kaushal J, Nakano I, Mizowaki T, Sasayama T, Tanaka K, Mizukawa K, Nishihara M, Nakamizo S, Tanaka H, Kohta M, Hosoda K, Kohmura E, Moeckel S, Meyer K, Leukel P, Bogdahn U, Riehmenschneider MJ, Bosserhoff AK, Spang R, Hau P, Mukasa A, Watanabe A, Ogiwara H, Saito N, Aburatani H, Mukherjee J, Obha S, See W, Pieper R, Nakajima K, Hara K, Kageji T, Mizobuchi Y, Kitazato K, Fujihara T, Otsuka R, Kung D, Nagahiro S, Rajbhandari R, Sinha T, Meares G, Benveniste EN, Nozell S, Ott M, Litzenburger U, Rauschenbach K, Bunse L, Pusch S, Ochs K, Sahm F, Opitz C, von Deimling A, Wick W, Platten M, Peruzzi P, Chiocca EA, Godlewski J, Read R, Fenton T, Gomez G, Wykosky J, Vandenberg S, Babic I, Iwanami A, Yang H, Cavenee W, Mischel P, Furnari F, Thomas J, Ronellenfitsch MW, Thiepold AL, Harter PN, Mittelbronn M, Steinbach JP, Rybakova Y, Kalen A, Sarsour E, Goswami P, Silber J, Harinath G, Aldaz B, Fabius AWM, Turcan S, Chan TA, Huse JT, Sonabend AM, Bansal M, Guarnieri P, Lei L, Soderquist C, Leung R, Yun J, Kennedy B, Sisti J, Bruce S, Bruce R, Shakya R, Ludwig T, Rosenfeld S, Sims PA, Bruce JN, Califano A, Canoll P, Stockhausen MT, Kristoffersen K, Olsen LS, Poulsen HS, Stringer B, Day B, Barry G, Piper M, Jamieson P, Ensbey K, Bruce Z, Richards L, Boyd A, Sufit A, Burleson T, Le JP, Keating AK, Sundstrom T, Varughese JK, Harter P, Prestegarden L, Petersen K, Azuaje F, Tepper C, Ingham E, Even L, Johnson S, Skaftnesmo KO, Lund-Johansen M, Bjerkvig R, Ferrara K, Thorsen F, Takeshima H, Yamashita S, Yokogami K, Mizuguchi S, Nakamura H, Kuratsu J, Fukushima T, Morishita K, Tanaka H, Sasayama T, Tanaka K, Nakamizo S, Mizukawa K, Kohmura E, Tang Y, Vaka D, Chen S, Ponnuswami A, Cho YJ, Monje M, Tateishi K, Narita Y, Nakamura T, Cahill D, Kawahara N, Ichimura K, Tiemann K, Hedman H, Niclou SP, Timmer M, Tjiong R, Rohn G, Goldbrunner R, Timmer M, Tjiong R, Stavrinou P, Rohn G, Perrech M, Goldbrunner R, Tokita M, Mikheev S, Sellers D, Mikheev A, Kosai Y, Rostomily R, Tritschler I, Seystahl K, Schroeder JJ, Weller M, Wade A, Robinson AE, Phillips JJ, Gong Y, Ma Y, Cheng Z, Thompson R, Wang J, Fan QW, Cheng C, Gustafson W, Charron E, Zipper P, Wong R, Chen J, Lau J, Knobbe-Thosen C, Weller M, Jura N, Reifenberger G, Shokat K, Weiss W, Wu S, Fu J, Zheng S, Koul D, Yung WKA, Wykosky J, Hu J, Taylor T, Villa GR, Gomez G, Mischel PS, Gonias SL, Cavenee W, Furnari F, Yamashita D, Kondo T, Takahashi H, Inoue A, Kohno S, Harada H, Ohue S, Ohnishi T, Li P, Ng J, Yuelling L, Du F, Curran T, Yang ZJ, Zhu D, Castellino RC, Van Meir EG, Zhu W, Begum G, Wang Q, Clark P, Yang SS, Lin SH, Kahle K, Kuo J, Sun D. CELL BIOLOGY AND SIGNALING. Neuro Oncol 2013. [DOI: 10.1093/neuonc/not174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Tateishi K, Tateishi U, Nakanowatari S, Ohtake M, Minamimoto R, Suenaga J, Murata H, Kubota K, Inoue T, Kawahara N. (62)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) PET in human gliomas: comparative study with [(18)F]fluorodeoxyglucose and L-methyl-[(11)C]methionine PET. AJNR Am J Neuroradiol 2013; 35:278-84. [PMID: 23928140 DOI: 10.3174/ajnr.a3679] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND AND PURPOSE (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone) was developed as a hypoxic radiotracer in PET. We compared imaging features among MR imaging and (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone)-PET, FDG-PET, and L-methyl-[(11)C]methionine)-PET in gliomas. MATERIALS AND METHODS We enrolled 23 patients who underwent (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone)-PET and FDG-PET and 19 (82.6%) who underwent L-methyl-[(11)C]methionine)-PET, with all 23 patients undergoing surgery and their diagnosis being then confirmed by histologic examination as a glioma. Semiquantitative and volumetric analysis were used for the comparison. RESULTS There were 10 newly diagnosed glioblastoma multiforme and 13 nonglioblastoma multiforme (grades II and III), including 4 recurrences without any adjuvant treatment. The maximum standardized uptake value and tumor/background ratios of (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone), as well as L-methyl-[(11)C]methionine, were significantly higher in glioblastoma multiforme than in nonglioblastoma multiforme (P = .03 and P = .03, respectively); no significant differences were observed on FDG. At a tumor/background ratio cutoff threshold of 1.9, (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone) was most predictive of glioblastoma multiforme, with 90.0% sensitivity and 76.9% specificity. The positive and negative predictive values, respectively, for glioblastoma multiforme were 75.0% and 85.7% on (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone), 83.3% and 60.0% on L-methyl-[(11)C]methionine, and 72.7% and 75.0% on MR imaging. In glioblastoma multiforme, volumetric analysis demonstrated that (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone) uptake had significant correlations with FDG (r = 0.68, P = .03) and L-methyl-[(11)C]methionine (r = 0.87, P = .03). However, the (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone)-active region was heterogeneously distributed in 50.0% (5/10) of FDG-active and 0% (0/6) of L-methyl-[(11)C]methionine)-active regions. CONCLUSIONS (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone) may be a practical radiotracer in the prediction of glioblastoma multiforme. In addition to FDG-PET, L-methyl-[(11)C]methionine)-PET, and MR imaging, (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone)-PET may provide intratumoral hypoxic information useful in establishing targeted therapeutic strategies for patients with glioblastoma multiforme.
Collapse
Affiliation(s)
- K Tateishi
- From the Departments of Neurosurgery (K.T., S.N., M.O., J.S., H.M., N.K.)
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, Inoue T, Kawahara N. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma. AJNR Am J Neuroradiol 2013; 34:92-9. [PMID: 22700754 DOI: 10.3174/ajnr.a3159] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND AND PURPOSE Hypoxic tissue evaluation in glioma is important for predicting treatment response and establishing antihypoxia therapy. In this preliminary study, (62)Cu-ATSM PET was used to determine its validity as a biomarker for distinguishing tumor grade and tissue hypoxia. MATERIALS AND METHODS (62)Cu-ATSM PET was performed in 22 patients with glioma, and the (62)Cu-ATSM SUV(max) and T/B ratio were semiquantitatively evaluated. (62)Cu-ATSM uptake distribution was qualitatively evaluated and compared with MR imaging findings. HIF-1α expression, a hypoxia marker, was compared with (62)Cu-ATSM uptake values. RESULTS The (62)Cu-ATSM SUV(max) and T/B ratio were significantly higher in grade IV than in grade III gliomas (P = .014 and .018, respectively), whereas no significant differences were found between grade III and grade II gliomas. At a T/B ratio cutoff threshold of 1.8, (62)Cu-ATSM uptake was predictive of HIF-1α expression, with 92.3% sensitivity and 88.9% specificity. The mean T/B ratio was also significantly higher in HIF-1α-positive glioma tissue than in HIF-1α-negative tissue (P = .001). Using this optimal threshold of T/B ratio, (62)Cu-ATSM PET showed regional uptake in 61.9% (13/21) of tumors within the contrast-enhanced region on MR imaging, which was significantly correlated with presence of a necrotic component (P = .002). CONCLUSIONS Our results demonstrated that (62)Cu-ATSM uptake is relatively high in grade IV gliomas and correlates with the MR imaging findings of necrosis. Moreover, the (62)Cu-ATSM T/B ratio showed significant correlation with HIF-1α expression. Thus, (62)Cu-ATSM appears to be a suitable biomarker for predicting highly malignant grades and tissue hypoxia in patients with glioma.
Collapse
Affiliation(s)
- K Tateishi
- Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Kawahara N, Higurashi M, Tateishi K. Results of Surgery for Jugular Foramen Schwannoma. Skull Base Surg 2012. [DOI: 10.1055/s-0032-1314306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
25
|
Negoro M, Nakayama K, Tateishi K, Kagawa A, Takeda K, Kitagawa M. H2-decoupling-accelerated H1 spin diffusion in dynamic nuclear polarization with photoexcited triplet electrons. J Chem Phys 2010; 133:154504. [DOI: 10.1063/1.3493453] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Tateishi K, Ando W, Higuchi C, Hart DA, Hashimoto J, Nakata K, Yoshikawa H, Nakamura N. Comparison of human serum with fetal bovine serum for expansion and differentiation of human synovial MSC: potential feasibility for clinical applications. Cell Transplant 2009; 17:549-57. [PMID: 18714674 DOI: 10.3727/096368908785096024] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The aim of this study was to evaluate the effect of human serum (HS) on growth and differentiation capacity of human synovium-derived mesenchymal stem cells (MSC) in comparison to cells grown in fetal bovine serum (FBS). Human MSCs were isolated from the synovium of knee joints of three donors and the cells were cultured individually in varying concentrations of allogenic HS or FBS. Bovine MSCs were isolated from synovium and cultured in the same manner. Cell proliferation was assessed by the tetrazolium assay after passage 3. The capacity for chondrogenic and osteogenic differentiation was investigated in specific media followed by 1,9-dimethylmethylene blue assay and alcian blue staining, or by alizarin red staining, respectively. Human MSCs proliferated significantly more rapidly in the presence of HS than with equivalent levels of FBS. Chondrogenic or osteogenic differentiation occurred to nearly identical levels in HS or FBS. The results of this study indicate that HS is superior for the culture of human MSCs compared with FBS in terms of cellular expandability, without losing chondrogenic or osteogenic differentiation capacity. Coupled with the advantage in eliminating the potential risk accompanied with the use of xeno-derived materials, pooled, well-characterized HS could be a useful reagent to promote cellular expansion for clinical synovial stem cell-based therapy.
Collapse
Affiliation(s)
- K Tateishi
- Department of Orthopedics, National Hospital Organization Kure Medical Center, Hiroshima, Japan
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Katakai D, Imura M, Ando W, Tateishi K, Yoshikawa H, Nakamura N, Fujie H. Compressive properties of cartilage-like tissues repaired in vivo with scaffold-free, tissue engineered constructs. Clin Biomech (Bristol, Avon) 2009; 24:110-6. [PMID: 18990475 DOI: 10.1016/j.clinbiomech.2008.07.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2007] [Revised: 07/15/2008] [Accepted: 07/15/2008] [Indexed: 02/07/2023]
Abstract
BACKGROUND It is crucial to develop an effective methodology for restoring adequate compressive properties to osteoarthritic cartilage. We have developed a scaffold-free tissue engineered construct cultured from synovium-derived mesenchymal stem cells. However, the compressive properties of cartilage-like tissues repaired with the construct have not been fully determined. METHODS Synovium-derived mesenchymal stem cells were cultured in Dulbecco's modified Eagle's medium to produce the tissue engineered construct. Implantation of the construct into cylindrically-shaped partial defects in femoral cartilage in an experimental porcine model was performed. Six months after implantation, cartilage-like tissues repaired with the construct were subjected to static and cyclic compression tests using a micro-unconfined compression test apparatus developed in our laboratory. FINDINGS The developed apparatus was validated in preliminary examinations. The repaired tissues exhibited rate-dependent viscoelastic properties; the compressive modulus was slightly lower than that of normal cartilage at a rate of 4 microm/s, while no difference was observed at a rate of 100 microm/s. In contrast, the repaired tissue without the construct exhibited rate-independent, non-viscoelastic properties. In the cyclic compression test, however, the compressive strain was significantly larger in both repaired tissues as compared with normal cartilage. INTERPRETATION Although the quasi-static compressive properties of the repaired tissue with the construct, indicating rate-dependent and viscoelastic behaviors, are comparable to normal cartilage, the cyclic compressive strain increases more rapidly than in normal cartilage. It is suggested that the differences between the tissues and normal cartilage are attributable to the increased permeability of the extracellular matrix.
Collapse
Affiliation(s)
- D Katakai
- Biomechanics Laboratory, Department of Mechanical Engineering, Kogakuin University, 2665-1 Nakanomachi, Hachioji, Tokyo 192-0015, Japan
| | | | | | | | | | | | | |
Collapse
|
28
|
Ishizawa N, Tateishi K. Polaronic behavior of Mn 4O 4heterocubane clusters in LiMn 2O 4spinel. Acta Crystallogr A 2008. [DOI: 10.1107/s010876730809507x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
29
|
Tateishi K, Higuchi C, Ando W, Nakata K, Hashimoto J, Hart DA, Yoshikawa H, Nakamura N. The immunosuppressant FK506 promotes development of the chondrogenic phenotype in human synovial stromal cells via modulation of the Smad signaling pathway. Osteoarthritis Cartilage 2007; 15:709-18. [PMID: 17292639 DOI: 10.1016/j.joca.2007.01.006] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2006] [Accepted: 01/02/2007] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To assess the effect of the immunosuppressant FK506 on chondrogenic differentiation of human synovial stromal cells (hSSCs). METHODS hSSCs were isolated from synovium of the knee joint and 2x10(5) cells were subjected to pellet culture in chondrogenic culture medium for 3 weeks with or without growth factors [bone morphogenetic protein 2 (BMP2) or transforming growth factor beta(1) (TGFbeta(1))] and +/- addition of FK506 in chondrogenic culture media was evaluated. Chondrogenesis was assessed by the size of the pellet, the production of proteoglycans, and messenger RNA (mRNA) levels for chondrogenic markers. Furthermore, levels and intracellular location of phosphorylated Smad proteins related to BMP signaling and TGFbeta signaling were evaluated following exposure to FK506. RESULTS FK506 enhanced the differentiation of hSSCs toward a chondrogenic phenotype in a dose-dependent manner associated with increases in glycosaminoglycan synthesis and increased mRNA levels for chondrogenic marker genes. Additionally, FK506 further enhanced chondrogenesis of synovial stromal cells (SSCs) induced by BMP2 and TGFbeta(1), also in a dose-dependent manner. Notably, phosphorylation of Smad1/5/8 and Smad3 was significantly increased by FK506. Also, the ratio of nuclear translocation to cytoplasmic levels of phosphorylated Smad1/5/8 and Smad3 were increased following exposure of SSCs to FK506. Moreover, inhibition of Smad signaling significantly abrogated FK506-induced chondrogenic differentiation of SSCs. CONCLUSION This study demonstrated that FK506 promotes chondrogenic differentiation of hSSCs likely via impact on Smad signaling pathways. With further optimization, FK506 could potentially be a unique therapeutic tool to promote cartilage repair in clinical situations, as well as enhance development of tissue engineered cartilage in vitro.
Collapse
Affiliation(s)
- K Tateishi
- Department of Orthopaedics, Osaka University Graduate School of Medicine, Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Tanaka Y, Kanai F, Ichimura T, Tateishi K, Asaoka Y, Guleng B, Jazag A, Ohta M, Imamura J, Ikenoue T, Ijichi H, Kawabe T, Isobe T, Omata M. The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene 2006; 25:633-42. [PMID: 16247477 DOI: 10.1038/sj.onc.1209093] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Hepatitis B virus X protein (HBx) has many cellular functions and is a major factor in hepatitis and hepatocellular carcinoma caused by HBV infection. A proteomic approach was used to search for HBx-interacting proteins in order to elucidate the molecular mechanism of hepatocarcinogenesis. HBx was attached to myc and flag tags (MEF tags) and expressed in 293T cells; the protein complex formed within the cells was purified and characterized by mass spectrometry. COP9 signalosome (CSN) subunits 3 and 4 were subsequently identified as HBx-interacting proteins. In addition, CSN subunit 5, Jun activation domain-binding protein 1 (Jab1), was shown to be a novel cellular target of HBx. In vivo and in vitro interactions between HBx and Jab1 were confirmed by standard immunoprecipitation and GST pull-down assays. An analysis of HBx deletion constructs showed that amino acids 30-125 of HBx were responsible for binding to Jab1. Confocal laser microscopy demonstrated that HBx was mainly localized in the cytoplasm, while Jab1 was found mainly in the nucleus and partially in the cytoplasm, and that the two proteins colocalized in the cytoplasm. The cotransfection of HBx and Jab1 resulted in substantial activator protein 1 (AP-1) activation and knockdown of endogenous Jab1 attenuated AP-1 activation caused by HBx. In addition, the coexpression of HBx and Jab1 potentiated phosphorylation of JNK, leading to the subsequent phosphorylation of c-Jun, whereas the level of c-Jun and JNK phosphorylation induced by HBx was decreased in Jab1 knockdown cells. These results suggest that the interaction between HBx and Jab1 enhances HBx-mediated AP-1 activation.
Collapse
Affiliation(s)
- Y Tanaka
- Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Chang J, Kato N, Taniguchi H, Bayasi G, Tateishi K, Jazag A, Dharel N, Moriyama M, Muroyama R, Shao R, Kawabe T, Omata M. O.086 Inhibition of hepatitis C virus replication by PKR. J Clin Virol 2006. [DOI: 10.1016/s1386-6532(06)80086-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
32
|
Katakai D, Fujie H, Imura M, Ando W, Tateishi K, Yoshikawa H, Nakamura N. In vivo cartilage regeneration using a scaffold-free 3-D synthetic tissue cultured from synovium-derived cells. J Biomech 2006. [DOI: 10.1016/s0021-9290(06)85382-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
33
|
Tanaka Y, Kanai F, Tada M, Asaoka Y, Guleng B, Jazag A, Ohta M, Ikenoue T, Tateishi K, Obi S, Kawabe T, Yokosuka O, Omata M. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 2005; 25:2950-2. [PMID: 16331247 DOI: 10.1038/sj.onc.1209311] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A recent study revealed that the p110alpha (PIK3CA), catalytic subunit of phosphatidylinositol 3-kinase (PI3K), is somatically mutated in many types of cancer. For example, PIK3CA is mutated in an estimated 35.6% of hepatocellular carcinoma (HCC) cases. To measure the frequency of PIK3CA hotspot mutations in Japanese HCC patients, exons 9 and 20 of the PIK3CA gene were sequenced in 47 clinical HCC samples. Contrary to expectations, no hotspot mutations were found any of the HCC samples. In addition, we found abnormally migrating waves near the end of exon 9 in the PCR chromatograms from 13 of the 47 samples. PCR amplification and subsequent cloning and sequencing revealed that these chromatograms contained two distinct sequences, the wild-type p110alpha sequence and a different sequence found on human chromosome 22q11.2, the Cat Eye Syndrome region, which contains a putative pseudogene of PIK3CA. These abnormally migrating waves were also found in noncancerous liver tissue, indicating that this was not a result of HCC-associated mutations. Therefore, it is likely that the percentage of hotspot mutations in the PIK3CA gene of Japanese HCC patients is lower than was previously reported.
Collapse
Affiliation(s)
- Y Tanaka
- Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Ishizawa N, Tateishi K, du Boulay D. The effect of Fourier series truncation errors on the electron density distribution of LiMn 2O 4. Acta Crystallogr A 2005. [DOI: 10.1107/s0108767305082188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
35
|
Muroi Y, Nakata K, Nakamura N, Ando W, Tateishi K, Yoshikawa H, Kakudo K. Development and characterization of three-dimensional culture system of the synovium-derived stem cells in a collagen scaffold with collagen gel for tissue engineering and reproductive medicine. Int J Oral Maxillofac Surg 2005. [DOI: 10.1016/s0901-5027(05)81438-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
36
|
Tateishi K, Kitayama N, Ishikawa H, Mitsudome A, Hirose S. Effect of growth hormone on high plasma levels of glucagon-like peptide-1 (GLP-1) in hypophysectomized rats. Exp Clin Endocrinol Diabetes 2002; 110:361-3. [PMID: 12397536 DOI: 10.1055/s-2002-34994] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Fasting plasma GLP-1 levels were significantly higher in hypophysectomized (hypox) rats (n = 6) than in intact (normal) rats (n = 7) (54.3 +/- 5.2 vs. 33.3 +/- 2.4 pmol/L, p < 0.001). To examine the influence of pituitary hormones on plasma GLP-1 levels, concentrations of plasma glucose, insulin and GLP-1 after an oral glucose load to hypox rats that were given either rat growth hormone (rGH) (n = 7), cortisol and thyroxine (n = 7) or no substitution (n = 6) were compared with those of normal rats (n = 7). Plasma glucose levels in the fasting state and after the glucose ingestion were significantly lower in hypox rats, but the hormonal replacements to hypox rats increased their total glucose levels to those of normal rats, although the increasing patterns were different from those in normal rats. Insulin levels both in the fasting state and after the glucose ingestion were significantly decreased in hypox rats and the fasting and total GLP-1 levels were significantly increased in those rats. rGH substitution significantly increased the total insulin levels in hypox rats and decreased the fasting and total GLP-1 levels closely to levels in normal rats, while substitution with cortisol and thyroxine failed to introduce such a significant effect. These results suggested that secretion of GLP-1 might be influenced by the function of GH.
Collapse
Affiliation(s)
- K Tateishi
- Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan.
| | | | | | | | | |
Collapse
|
37
|
Tateishi K, du Boulay DJ, Ishizawa N. Molecular dynamics simulations of LiMn 2O 4spinel. Acta Crystallogr A 2002. [DOI: 10.1107/s0108767302095740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
38
|
Abstract
A 21-year-old man was troubled with a subacute history of brainstem involvement and a leukocyte pleocytosis in the cerebrospinal fluid. Magnetic resonance imaging (MRI) demonstrated a massive lesion with Gd enhancement in the pons. Steroid therapy, not antiviral drugs, was dramatically effective for the mass reduction and symptom improvement. Over 4 years no recurrence has been recognized, so this case was diagnosed to be an unusual case of acute disseminated encephalomyelitis (ADEM). ADEM must be included in the differential diagnosis for a brainstem mass in MRI.
Collapse
Affiliation(s)
- K Tateishi
- Department of Second Internal Medicine, Tokyo University, Bunkyo-Ku, Hongo 7-3-1, Tokyo 1138655, Japan.
| | | | | |
Collapse
|
39
|
Abstract
NEDD8/Rub1 is a ubiquitin (Ub)-like molecule that covalently ligates to target proteins through an enzymatic cascade analogous to ubiquitylation. This modifier is known to target all cullin (Cul) family proteins. The latter are essential components of Skp1/Cul-1/F-box protein (SCF)-like Ub ligase complexes, which play critical roles in Ub-mediated proteolysis. To determine the role of the NEDD8 system in mammals, we generated mice deficient in Uba3 gene that encodes a catalytic subunit of NEDD8-activating enzyme. Uba3(-/-) mice died in utero at the periimplantation stage. Mutant embryos showed selective apoptosis of the inner cell mass but not of trophoblastic cells. However, the mutant trophoblastic cells could not enter the S phase of the endoreduplication cycle. This cell cycle arrest was accompanied with aberrant expression of cyclin E and p57(Kip2). These results suggested that the NEDD8 system is essential for both mitotic and the endoreduplicative cell cycle progression. beta-Catenin, a mediator of the Wnt/wingless signaling pathway, which degrades continuously in the cytoplasm through SCF Ub ligase, was also accumulated in the Uba3(-/-) cytoplasm and nucleus. Thus, the NEDD8 system is essential for the regulation of protein degradation pathways involved in cell cycle progression and morphogenesis, possibly through the function of the Cul family proteins.
Collapse
Affiliation(s)
- K Tateishi
- Department of Molecular Oncology, Tokyo Metropolitan Institute of Medical Science, Bunkyo-Ku, Tokyo 113-8613, Japan
| | | | | | | |
Collapse
|
40
|
Tateishi K, DiMagno EP, Klee GG. Plasma islet amyloid polypeptide is not an effective tumor marker for pancreatic cancer even when protease inhibitors and rapid freezing of specimens are utilized. Clin Chem 2001; 47:2071-3. [PMID: 11673391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
|
41
|
Miyasaka K, Masuda M, Kanai S, Ohta M, Suzuki S, Tateishi K, Funakoshi A. Inhibitory effect of somatostatin on cholecystokinin release is independent of luminal cholecystokinin-releasing factor content in conscious rats. Pancreas 2001; 23:414-20. [PMID: 11668212 DOI: 10.1097/00006676-200111000-00013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
INTRODUCTION Exclusion of bile-pancreatic juice from the intestine increases pancreatic secretion via cholecystokinin (CCK) release in conscious rats. Luminal CCK-releasing factor (LCRF), purified from rat intestinal secretions, is an intraluminal regulator of CCK secretion during bile-pancreatic juice diversion. AIMS Because somatostatin is a potent inhibitor of CCK release and pancreatic secretion, the inhibitory effect of somatostatin on LCRF was examined. METHODOLOGY Rats were prepared with bile and pancreatic cannulae and two duodenal cannulae and with an external jugular vein cannula. The experiments were conducted without anesthesia. After 1.5-hour basal collection of pancreatic juice with bile-pancreatic juice return, bile-pancreatic juice was diverted for 2 hours, during which time somatostatin (2, 10 nmol/kg/h) was infused intravenously. The rats were killed before and 1 and 2 hours after bile-pancreatic juice diversion. To examine the effect of luminal somatostatin, 50 or 200 nmol/kg/h of somatostatin was infused into the duodenum. The plasma CCK and luminal content of LCRF were measured by specific radioimmunoassays. RESULTS Bile-pancreatic juice diversion significantly increased pancreatic secretion, plasma CCK, and LCRF levels. Intravenous infusion of somatostatin inhibited CCK release and pancreatic secretion, but not LCRF content. Luminal administration of somatostatin did not show any effect. CONCLUSION Inhibitory effect of circulating somatostatin on CCK release and pancreatic secretion is independent of LCRF content.
Collapse
Affiliation(s)
- K Miyasaka
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakaecho, Itabashiku, Tokyo-173-0015, Japan.
| | | | | | | | | | | | | |
Collapse
|
42
|
Ohashi M, Kanai F, Tateishi K, Taniguchi H, Marignani PA, Yoshida Y, Shiratori Y, Hamada H, Omata M. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Biochem Biophys Res Commun 2001; 282:529-35. [PMID: 11401492 DOI: 10.1006/bbrc.2001.4573] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Gene therapy using replication-competent adenovirus that selectively propagates in tumor cells may be an effective treatment for cancer. We developed an adenovirus that would be replication specific for hepatocellular carcinoma (HCC). Based on our finding that the E1B55k-deficient adenovirus was able to replicate in human primary hepatocytes, we therefore designed an adenovirus carrying E1A and attenuated E1B gene driven by the alpha-fetoprotein promoter (Adv-AFP-E1AdB), thus restricting the replication specificity in AFP-producing HCC. Replication of Adv-AFP-E1AdB in primary hepatocytes was practically negligible 4 days after infection. Although Adv-AFP-E1AdB replicated slowly in AFP-producing HCC, it efficiently destroyed HCC cells independent of their p53 status. Experiments were conducted in vivo using systemic administration of Adv-AFP-E1AdB and we observed tumor size reduction in nude mice having liver cancer. The use of replication-competent adenovirus deficient of the E1B gene coupled to an AFP-targeting strategy may be a safe and efficacious treatment for HCC.
Collapse
MESH Headings
- Adenoviridae/genetics
- Adenoviridae/physiology
- Animals
- Carcinoma, Hepatocellular/metabolism
- Carcinoma, Hepatocellular/therapy
- Cytopathogenic Effect, Viral
- Defective Viruses/genetics
- Defective Viruses/physiology
- Female
- Genetic Therapy
- Hepatocytes/metabolism
- Hepatocytes/virology
- Humans
- Liver Neoplasms/metabolism
- Liver Neoplasms/therapy
- Liver Neoplasms, Experimental/metabolism
- Liver Neoplasms, Experimental/pathology
- Liver Neoplasms, Experimental/therapy
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Mutation
- Promoter Regions, Genetic
- Tumor Cells, Cultured
- Virus Replication
- alpha-Fetoproteins/biosynthesis
- alpha-Fetoproteins/genetics
Collapse
Affiliation(s)
- M Ohashi
- Department of Gastroenterology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
It has recently been determined that the proteolytic destruction of IkappaB (inhibitor of NF-kappaB) by the ubiquitin-proteasome system plays a key role in the immediate elimination of IkappaB from the IkappaB-(NF-kappaB) complex which allows nuclear translocation of free NF-kappaB, thus leading to activation of a multitude of target genes. The SCF(Fbw1) (composed of Skp1, Cul-1, Roc1, and Fbw1) complex, identified as an IkappaBalpha-E3 ligase, binds and ubiquitylates IkappaBalpha phosphorylated by IkappaB kinase that has been activated in response to extracellular signals. The generating poly-ubiquitin chain is finally recognized by the 26S proteasome for ultimate degradation. In this NF-kappaB signalling pathway, it becomes clear that the SCF(Fbw1) activity is enhanced by a ubiquitin-like protein NEDD8 (equivalent to Rub1) that modifies Cul-1 in a manner analogous to ubiquitylation, and consequently, IkappaBalpha proteolysis is induced. NEDD8 is a new regulator of the SCF ubiquitin-ligase, functioning as a covalent modifier for proteolytic targeting at a physiological level.
Collapse
Affiliation(s)
- K Tanaka
- The Tokyo Metropolitan Institute of Medical Science, and CREST, Japan Science and Technology Corporation (JST), 113-8613, Tokyo, Japan.
| | | | | | | | | |
Collapse
|
44
|
Sakagashira S, Hiddinga HJ, Tateishi K, Sanke T, Hanabusa T, Nanjo K, Eberhardt NL. S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin. Am J Pathol 2000; 157:2101-9. [PMID: 11106582 PMCID: PMC1885776 DOI: 10.1016/s0002-9440(10)64848-1] [Citation(s) in RCA: 110] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Human amylin, a major constituent of pancreatic amyloid deposits, may be a pathogenetic factor for noninsulin-dependent diabetes mellitus (NIDDM). We demonstrated that the human amylin S20G gene mutation (S20G) was associated with a history of early onset, more severe type of NIDDM, linking the amylin gene to this disease. Also, we demonstrated that expression of human wild-type (WT) amylin in COS-1 cells leads to intracellular amyloidogenesis and induction of apoptosis, suggesting a possible mechanism for disease induction. Therefore we compared the abilities of S20G and WT amylin to induce apoptosis in transfected COS-1 cells and form amyloid in vitro. We transfected the rat (RAT), mutated human (MUT), WT, and S20G amylin genes into COS-1 cells and measured apoptosis using fluorescent-activated cell sorting analysis at 48, 72, and 96 hours. At 96 hours apoptosis increased significantly (P < 0.01) in cells transfected with WT and S20G over RAT or MUT (WT, 19%; S20G, 25%; RAT, 13%; and MUT, 12%) and the difference between WT and S20G was significant (P < 0.05). Synthetic WT and S20G monomeric peptides were used to generate amyloid fibrils in vitro as measured by the thioflavin T binding assay. The S20G amylin formed approximately twofold more amyloid at a rate approximately threefold higher than WT. Electron micrography indicated that the in vitro amyloid generated by WT and S20G amylins were morphologically indistinguishable. The results suggest that increased cytotoxicity by S20G is because of increased amyloidogenicity, which may be a causative factor in the early development of NIDDM, possibly through loss of ss cell mass.
Collapse
Affiliation(s)
- S Sakagashira
- Departments of Medicine, Biochemistry and Molecular Biology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
| | | | | | | | | | | | | |
Collapse
|
45
|
Tateishi K, Tada M, Yamagata M, Isayama H, Komatsu Y, Kawabe T, Shiratori Y, Omata M. High proportion of mutant K-ras gene in pancreatic juice of patients with pancreatic cystic lesions. Gut 1999; 45:737-40. [PMID: 10517912 PMCID: PMC1727731 DOI: 10.1136/gut.45.5.737] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
Abstract
BACKGROUND/AIMS It was recently reported that the quantitative analysis of mutant K-ras gene in pancreatic juice could be useful for the diagnosis of pancreatic cancer. This methodology was applied to patients with pancreatic cystic lesions. METHODS DNA was extracted from pancreatic juice collected at the time of endoscopy with injection of secretin. The ratio of the K-ras mutant allele to the wild-type allele was measured by two methods to detect and semiquantify mutant K-ras gene: polymerase chain reaction/preferential homoduplex formation assay and enriched polymerase chain reaction/enzyme linked mini-sequence assay. RESULTS A high frequency of K-ras mutation was detected (more than 2% of all K-ras genes) in six of 14 patients (43%) with pancreatic cysts. This frequency was similar to those detected in patients with pancreatic adenocarcinoma and in intraductal papillary neoplasms of the pancreas. In contrast, the frequency of mutation was low (less than 2%) in patients without either pancreatic cysts or pancreatic neoplasms. CONCLUSIONS K-ras gene mutation may be derived from duct cells in the pancreas with a high potential for tumorigenesis. Therefore careful follow up of patients with a pancreatic cyst is recommended if they are found to have a high level of the mutant gene in the pancreatic juice.
Collapse
Affiliation(s)
- K Tateishi
- Department of Gastroenterology, University of Tokyo, Tokyo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Tateishi K, Misumi Y, Ikehara Y, Miyasaka K, Funakoshi A. Molecular cloning and expression of rat antisecretory factor and its intracellular localization. Biochem Cell Biol 1999; 77:223-8. [PMID: 10505793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
Antisecretory factor (AF) was identified as a pituitary protein that inhibits the intestinal fluid secretion induced by cholera toxin. One aim of this study was to elucidate whether AF is also synthesized in the intestine or if AF produced in the pituitary is transported to the intestinal tract for its function there. cDNA clones encoding a protein proposed to be AF were isolated from rat pituitary gland and intestinal mucosa cDNA libraries. The nucleotide sequences of clones isolated from the rat pituitary gland and intestinal mucosa were identical. The deduced amino acid sequence was highly homologous to the sequence for subunit 5a of the human 26S protease that exists abundantly in the cytosol and nucleus. The production of AF in the intestine was confirmed by Northern blot and immunoblot analyses. Immunocytochemical observations of cells transfected with the rat AF cDNA showed that the AF protein was localized in the cytoplasm. These findings suggest that the protein proposed to be AF may be a cytoplasmic protein, it exists in the intestine rather than being transported from the pituitary gland, and it may function in intestinal cells.
Collapse
Affiliation(s)
- K Tateishi
- Department of Biochemistry, Fukuoka University School of Medicine, Japan.
| | | | | | | | | |
Collapse
|
47
|
Matsuki N, Tateishi K, Takeuchi H, Yagisawa H, Kanematsu T, Oishi M, Hirata M. Antibodies against the PH domain of phospholipase C-delta1 inhibit Ins(1,4,5)P3-mediated Ca2+ release from the endoplasmic reticulum. Biochem Biophys Res Commun 1999; 260:42-7. [PMID: 10381341 DOI: 10.1006/bbrc.1999.0869] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The pleckstrin homology domain (PH domain) is now well known as a structural module for the binding of inositol compounds. In the present study, polyclonal antibodies against the peptide KVKSSSWRRERFYK, derived from the N-terminal of the PH domain of phospholipase C-delta1 (PLC-delta1), were raised in rabbits. These were then tested for their ability to inhibit the binding of inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] to the binding proteins including the receptor molecule. The Fab fragment of the antibodies but not the whole molecule inhibited the binding of Ins(1,4,5)P3 not only to PLC-delta1 but also to the Ins(1,4,5)P3 receptor, indicating that the antibodies raised recognized the binding site for Ins(1,4, 5)P3 in the receptor. Rat basophilic leukemic cells were permeabilized with saponin and assayed for Ins(1,4,5)P3-mediated Ca2+ release. Pretreatment of permeabilized RBL cells with the Fab fragment of the antibodies diminished the release of Ca2+ caused by Ins(1,4,5)P3, and further absorption experiments using a variety of synthetic peptides suggested that the tripeptide KVK is the epitope of the antibodies. Structural information about KVK will help in screening for Ins(1,4,5)P3 antagonists.
Collapse
Affiliation(s)
- N Matsuki
- Department of Biochemistry, Faculty of Dentistry, Fukuoka, 812-8582, Japan
| | | | | | | | | | | | | |
Collapse
|
48
|
Shimizu N, Itoh R, Hirono Y, Otera H, Ghaedi K, Tateishi K, Tamura S, Okumoto K, Harano T, Mukai S, Fujiki Y. The peroxin Pex14p. cDNA cloning by functional complementation on a Chinese hamster ovary cell mutant, characterization, and functional analysis. J Biol Chem 1999; 274:12593-604. [PMID: 10212238 DOI: 10.1074/jbc.274.18.12593] [Citation(s) in RCA: 134] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Rat cDNA encoding a 376-amino acid peroxin was isolated by functional complementation of a peroxisome-deficient Chinese hamster ovary cell mutant, ZP110, of complementation group 14 (CG14). The primary sequence showed 28 and 24% amino acid identity with the yeast Pex14p from Hansenula polymorpha and Saccharomyces cerevisiae, respectively; therefore, we termed this cDNA rat PEX14 (RnPEX14). Human and Chinese hamster Pex14p showed 96 and 94% identity to rat Pex14p, except that both Pex14p comprised 377 amino acids. Pex14p was characterized as an integral membrane protein of peroxisomes, exposing its N- and C-terminal parts to the cytosol. Pex14p interacts with both Pex5p and Pex7p, the receptors for peroxisome targeting signal type 1 (PTS1) and PTS2, respectively, together with the receptors' cargoes, PTS1 and PTS2 proteins. Mutation in PEX14 from ZP161, the same CG as ZP110, was determined by reverse transcription-PCR as follows. A 133-base pair deletion at nucleotide residues 37-169 in one allele created a termination codon at 40-42; in addition to this mutation, 103 base pairs were deleted at positions 385-487, resulting in the second termination immediately downstream the second deletion site in the other allele. Neither of these two mutant forms of Pex14p restored peroxisome biogenesis in ZP110 and ZP161, thereby demonstrating PEX14 to be responsible for peroxisome deficiency in CG14.
Collapse
Affiliation(s)
- N Shimizu
- Department of Biology, Kyushu University Faculty of Science, Fukuoka 812-8581, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Hiroyoshi M, Tateishi K, Yasunami Y, Maeshiro K, Ono J, Matsuoka Y, Ikeda S. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes. Am J Gastroenterol 1999; 94:976-81. [PMID: 10201468 DOI: 10.1111/j.1572-0241.1999.01043.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVE The purpose of the present study was to evaluate plasma glucagon-like peptide-1 (GLP-1) responses after oral glucose ingestion in patients with chronic pancreatitis and to clarify how GLP-1 secretion relates to pancreatic diabetes. METHODS An oral glucose tolerance test (OGTT) was performed in 17 patients with chronic pancreatitis. Plasma glucose, immunoreactive insulin (IRI), C-peptide, glucagon, and GLP-1 levels at each time point during OGTT were measured. The diagnosis of chronic pancreatitis was made by the findings of endoscopic retrograde pancreatography (ERP): evident dilation of the main pancreatic duct with or without pancreatolithiasis. RESULTS The patients were divided into three groups according to the World Health Organization classification of diabetes based on plasma glucose levels after OGTT. The groups were: normal (three patients), impaired glucose tolerant (IGT) (six patients), and diabetic (DM) (eight patients). In the DM group, IRI and C-peptide response levels after oral glucose ingestion were significantly reduced as compared with those of the normal and IGT groups. No significant glucagon responses to oral glucose ingestion were found in the three groups. In contrast, plasma GLP-1 levels were significantly elevated after oral glucose ingestion in the DM groups as compared with normal and IGT groups. CONCLUSIONS The present study affords evidence that plasma GLP-1 levels become elevated with development of pancreatic diabetes, although the precise mechanism of this elevation remains undetermined.
Collapse
Affiliation(s)
- M Hiroyoshi
- Department of Surgery, School of Medicine, Fukuoka University, Japan
| | | | | | | | | | | | | |
Collapse
|
50
|
Ohashi M, Kanai F, Ueno H, Tanaka T, Tateishi K, Kawakami T, Koike Y, Ikenoue T, Shiratori Y, Hamada H, Omata M. Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo. Gut 1999; 44:366-71. [PMID: 10026322 PMCID: PMC1727416 DOI: 10.1136/gut.44.3.366] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND/AIMS Gastric cancer is one of the most prevalent forms of cancer in East Asia. Point mutation of the p53 gene has been reported in more than 60% of cases of gastric cancer and can lead to genetic instability and uncontrolled cell proliferation. The purpose of this investigation was to evaluate the potential of p53 gene therapy for gastric cancer. METHODS The responses of human gastric cancer cell lines, MKN1, MKN7, MKN28, MKN45, and TMK-1, to recombinant adenoviruses encoding wild type p53 (AdCAp53) were analysed in vitro. The efficacy of the AdCAp53 treatment for MKN1 and MKN45 subcutaneous tumours in nude mice was assessed in vivo. RESULTS p53-specific growth inhibition was observed in vitro in two of four gastric cancer cell lines with mutated p53, but not in the wild type p53 cell line. The mechanism of the killing of gastric cancer cells by AdCAp53 was found, by flow cytometric analysis and detection of DNA fragmentation, to be apoptosis. In vivo studies showed that the growth of subcutaneous tumours of p53 mutant MKN1 cells was significantly inhibited by direct injection of AdCAp53, but no significant growth inhibition was detected in the growth of p53 wild type MKN45 tumours. CONCLUSIONS Adenovirus mediated reintroduction of wild type p53 is a potential clinical utility in gene therapy for gastric cancers.
Collapse
Affiliation(s)
- M Ohashi
- Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|